New in AJMC: Prioritizing Patient-Centered Value Over International Reference Pricing in U.S. Drug Policy
IVI is pleased to share a new commentary published in the AJMC® Contributor Column: “Prioritizing Patient-Centered Value Over International Reference Pricing in U.S. Drug Policy,” by Dominique Seo, MPH; Panos Kanavos, PhD; Eleanor M. Perfetto, PhD, MS; and Tiffany Huth, MPH. As policymakers consider international reference pricing (IRP) and most-favored nation (MFN) models as tools […]
IVI Announces the Appointment of Five New Board Members
IVI (IVI), a non-profit research organization committed to advancing the science, practice, and use of value assessment in healthcare announced the addition of five new members to its 2026 Board of Directors: Elizabeth Cope, PhD, MPH (Chief Programs & Science Officer, AcademyHealth), Amy Duhig, PHD (Senior Director, New Product Planning, Value and Evidence Generation, Takeda […]
IVI Calls for Stronger Patient Partnership and Real Consideration of Novel Value Elements in HEMA’s Draft Methods Report
In its public comments on the Health Economics Methods Advisory (HEMA) group’s draft report, “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies,” the IVI urged HEMA to strengthen its framework for defining benefits in economic evaluation. IVI called for patients and caregivers to be engaged as co-creators in methods development, for equity to […]
IVI Comments on the CMS Draft Guidance for the Medicare DPNP
IVI submitted comments on the draft guidance on the Medicare Drug Price Negotiation Program published on May 12, 2025.
IVI Responds to MFN Executive Order
Advancing patient-centered, evidence-based policy Alexandria, VA – May 13, 2025 – IVI released the following statement: IVI shares the goal of ensuring patients have affordable access to needed therapies. Controlling healthcare costs is essential to maintaining that access. However, the Most Favored Nation (MFN) pricing model is a blunt instrument that imports foreign price controls […]
Join IVI at ISPOR 2025
We are excited to present our research at ISPOR 2025 in Montreal, where our posters will contribute to the global dialogue on health economics and outcomes research (HEOR). In alignment with this year’s theme, “Collaborating to Improve Healthcare Decision Making for All: Expanding HEOR Horizons,” our work explores innovative methodologies and real-world data applications aimed […]
Discussing Patient Engagement in Health Technology Assessment for Rare Diseases
Rare diseases present unique challenges for health technology assessment (HTA), a critical tool for evaluating the value of new treatments.
IVI’s CEO Co-Authors Commentary on AI in Healthcare
Artificial intelligence (AI) rapidly transforms health care, enhancing diagnostic accuracy, drug development, and personalized patient care. Dr. Jason Spangler and John Nosta discuss AI’s potential to improve clinical trial design, real-time monitoring, and predictive modeling, increasing efficiency and outcomes. By processing vast data sets, AI reveals new patterns and advances in health economics and outcomes […]
IVI (formerly IVI) Provides Comments on CMS’ Drug Price Negotiation Program
The Innovation and Value Initiative (IVI) appreciates the opportunity to provide comments to IVIs for Medicare and Medicaid Services (CMS) on the revised draft guidance for implementation of the Medicare Drug Price Negotiation Program (DPNP) for initial price applicability year 2027 and manufacturer effectuation of the maximum fair price (MFP) in 2026 and 2027. Read […]
IVI to Present at ISPOR 2024 Annual Conference
Alexandria, VA – May 1, 2024 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of health technology assessment (HTA) in healthcare, today announced its participation at ISPOR 2024, May 5-8, 2024, at the Georgia World Congress Center in Atlanta. IVI will present six posters throughout […]